Effect of fasudil hydrochloride, a protein kinase inhibitor, on cerebral vasospasm and delayed cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage: Results of a randomized trial of fasudil hydrochloride versus nimodipine

Neurologia Medico-Chirurgica

Volumn 46, Issue 9, 2006, Pages 421-427

  Zhao, Jizong ^a   Zhou, Dingbiao ^b   Guo, Jing ^c   Ren, Zyuan ^d   Zhou, Liangfu ^e   Wang, Shuo ^a   Xu, Bainan ^b   Wang, Renzhi ^d  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b Department of Neurosurgery   (China)

^c CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^d PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^e FUDAN UNIVERSITY   (China)

Author keywords

Cerebral vasospasm; Fasudil hydrochloride; Nimodipine; Protein kinase inhibitor; Subarachnoid hemorrhage

Indexed keywords

FASUDIL; NIMODIPINE; PROTEIN KINASE INHIBITOR;

ADULT; ANEURYSM RUPTURE; ANEURYSM SURGERY; APHASIA; ARTICLE; BRAIN ARTERY ANEURYSM; BRAIN ISCHEMIA; BRAIN VASOSPASM; CLINICAL TRIAL; CONSCIOUSNESS LEVEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM HEMORRHAGE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLUSHING; GLASGOW OUTCOME SCALE; HUMAN; HYPOTENSION; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; NEUROLOGIC DISEASE; POSTOPERATIVE COMPLICATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUBARACHNOID HEMORRHAGE; TREATMENT RESPONSE;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ADULT; BRAIN ISCHEMIA; FEMALE; HUMANS; MALE; MIDDLE AGED; NIMODIPINE; PROTEIN KINASE INHIBITORS; SUBARACHNOID HEMORRHAGE; TREATMENT OUTCOME; VASODILATOR AGENTS; VASOSPASM, INTRACRANIAL;

EID: 33749021372     PISSN: 04708105     EISSN: 13498029     Source Type: Journal    
DOI: 10.2176/nmc.46.421     Document Type: Article

References (29)

1. Allen GS, Ahn HS, Preziosi TJ, Battye R, Boone SC, Chou SN, Kelly DL, Weir BK, Crabbe RA, Lavik PJ, Rosenbloom SB, Dorsey FC, Ingram CR, Mellitis DE, Bertsch LA, Boisvert DPJ, Hundley MB, Johnson RK, Strom JA, Transou CR: Cerebral arterial spasm - a controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med 308: 619-624, 1983
2. Arai M, Sasaki Y, Nozawa R: Inhibition by the protein kinase inhibitor HA1077 of the activation of NADPH oxidase in human neutrophils. Biochem Pharmacol 46: 1487-1490, 1993
3. Asano T, Ikegaki I, Satoh S, Mochizuki D, Hidaka H, Suzuki Y, Shibuya M, Sugita K: Blockade of intracellular actions of calcium may protect against ischaemic damage to the gerbil brain. Br J Pharmacol 103: 1935-1938, 1991
4. Asano T, Ikegaki I, Satoh S, Seto M, Sasaki Y: A protein kinase inhibitor, fasudil (AT-877): A novel approach to signal transduction therapy. Cardiovasc Drug Rev 16: 76-87, 1998
5. Asano T, Ikegaki I, Satoh S, Suzuki Y, Shibuya M, Sugita K, Hidaka H: Endothelin: a potential modulator of cerebral vasospasm. Eur J Pharmacol 190: 365-372, 1990
6. Asano T, Ikegaki I, Satoh S, Suzuki Y, Shibuya M, Takayasu M, Hidaka H: Mechanism of action of a novel antivasospasm drug, HA1077. J Pharmacol Exp Ther 241: 1033-1040, 1987
7. Asano T, Suzuki M, Tsuchiya S, Satoh S, Ikegaki I, Shibuya M, Suzuki Y, Hidaka H: Vasodilator actions of HA1077 in vitro and in vivo putatively mediated by the inhibition of protein kinase. Br J Pharmacol 98: 1091-1100, 1989
8. Hartshorne DJ, Mrwa U: Regulation of smooth muscle actomyosin. Blood Vessels 19: 1-18, 1982
9. Hitomi A, Satoh S, Ikegaki I, Suzuki Y, Shibuya M, Asano T: Hemorheological abnormalities in experimental cerebral ischemia and effects of protein kinase inhibitor on blood fluidity. Life Sci 67: 1929-1939, 2000
10. Kimura K, Ito M, Amano M, Chihara K, Fukata Y, Nakafuku M, Yamamori B, Feng J, Nakano AT, Okawa K, Iwamatsu A, Kaibuchi K: Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science 273: 245-248, 1996
11. Maiese K, Wagner J, Boccone L: Nitric oxide: a downstream mediator of calcium toxicity in the ischemic cascade. Neurosci Lett 166: 43-47, 1994
12. Nagumo H, Sasaki Y, Ono Y, Okamoto H, Seto M, Takuwa Y: Rho kinase inhibitor HA-1077 prevents Rho-mediated myosin phosphatase inhibition in smooth muscle cells. Am J Physiol Cell Physiol 278: C57-C65, 2000
13. 175 in porcine coronary artery. Eur J Pharmacol 360: 257-264, 1998
14. Neil-Dwyer G, Mee E, Dorrance D, Lowe D: Early intervention with nimodipine in subarachnoid hemorrhage. Eur Heart J 8 Suppl K: 41-47, 1987
15. Ohman J, Heiskanen O: Effect of nimodipine on the outcome of patients after aneurysmal subarachnoid hemorrhage and surgery. J Neurosurg 69: 683-686, 1988
16. Ohman J, Servo A, Heiskanen O: Long-term effects of nimodipine on cerebral infarcts and outcome after aneurysmal subarachnoid hemorrhage. J Neurosurg 74: 8-13, 1991
17. Petruk KC, West M, Mohr G, Weir BKA, Benoit BG, Gentill F, Disney LB, Khan MI, Grace M, Holness RO, Karwon MS, Ford RM, Cameron GS, Tuker WS, Purves GB, Miller JDR, Hunter KM, Richard MT, Durity FA, Chan R, Clein LJ, Maroun FB, Godon A: Nimodipine treatment in poor-grade aneurysm patients. Results of a multicenter double-blind placebo-controlled trial. J Neurosurg 68: 505-517, 1988
18. Philippon J, Grob R, Dagreou F, Guggiari M, Rivierez M, Viars P: Prevention of vasospasm in subarachnoid hemorrhage. A controlled study with nimodipine. Acta Neurochir (Wien) 82: 110-114, 1986
19. Sato M, Tani E, Fujikawa H, Kaibuchi K: Involvement of Rho-kinase-mediated phosphorylation of myosin light chain in enhancement of cerebral vasospasm. Circ Res 87: 195-200, 2000
20. Satoh S, Ikegaki I, Suzuki Y, Asano T, Shibuya M, Hidaka H: Neuroprotective properties of a protein kinase inhibitor against ischaemia-induced neuronal damage in rats and gerbils. Br J Pharmacol 118: 1592-1596, 1996
21. Satoh S, Kobayashi T, Hitomi A, Ikegaki I, Suzuki Y, Shibuya M, Yoshida J, Asano T: Inhibition of neutrophil migration by a protein kinase inhibitor for the treatment of ischemic brain infarction. Jpn J Pharmacol 80: 41-48, 1999
22. 2+ antagonist and vasodilator, on chronic cerebral vasospasm. Eur J Pharmacol 220: 243-248, 1992
23. Satoh S, Suzuki Y, Ikegaki I, Asano T, Shibuya M, Sugita K, Hidaka H: The effects of HA1077 on the cerebral circulation after subarachnoid haemorrhage in dogs. Acta Neurochir (Wien) 110: 185-188, 1991
24. Satoh S, Yamamoto Y, Toshima Y, Ikegaki I, Asano Y, Suzuki Y, Shibuya M: Fasudil, a protein kinase inhibitor, prevents the development of endothelial injury and neutrophil infiltration in a two-haemorrhage canine subarachnoid model. J Clin Neurosci 6: 394-399, 1999
25. Seto M, Sasaki Y, Sasaki Y, Hidaka H: Effect of HA1077, a protein kinase inhibitor, on myosin phosphorylation and tension in smooth muscle. Eur J Pharmacol 195: 267-272, 1991
26. Shibuya M, Suzuki Y, Sugita K, Saito I, Sasaki T, Takakura K, Nagata I, Kikuchi H, Takemae T, Hidaka H, Nakashima M: Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial. J Neurosurg 76: 571-577, 1992
27. Shibuya M, Suzuki Y, Takayasu M, Asano T, Harada T, Ikegaki I, Satoh S, Hidaka H: The effects of an intracellular calcium antagonist HA1077 on delayed cerebral vasospasm in dogs. Acta Neurochir (Wien) 90: 53-59, 1988
28. Shimokawa H, Seto M, Katsumata N, Amano M, Kozai T, Yamawaki T, Kuwata K, Kandabashi T, Egashira K, Ikegaki I, Asano T, Kaibuchi K, Takeshita A: Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm. Cardiovasc Res 43: 1029-1039, 1999
29. Tsuchiya M, Sako K, Yonemasu Y, Asano T: The effects of HA1077, a novel protein kinase inhibitor, on reductions of cerebral blood flow and glucose metabolism following acute and/or chronic bilateral carotid artery ligation in Wistar rats. Exp Brain Res 97: 233-238, 1993